Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HCW Biologics (HCWB) Research & Development (2020 - 2025)

HCW Biologics (HCWB) has disclosed Research & Development for 6 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development rose 18.31% year-over-year to $1.4 million, compared with a TTM value of $5.2 million through Sep 2025, down 30.99%, and an annual FY2024 reading of $6.4 million, down 16.77% over the prior year.
  • Research & Development was $1.4 million for Q3 2025 at HCW Biologics, up from $1.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $2.9 million in Q4 2022 and bottomed at $1.0 million in Q4 2024.
  • Average Research & Development over 5 years is $1.9 million, with a median of $1.8 million recorded in 2022.
  • The sharpest move saw Research & Development skyrocketed 97.53% in 2022, then crashed 50.87% in 2024.
  • Year by year, Research & Development stood at $1.5 million in 2021, then surged by 97.53% to $2.9 million in 2022, then decreased by 27.09% to $2.1 million in 2023, then plummeted by 50.87% to $1.0 million in 2024, then skyrocketed by 33.79% to $1.4 million in 2025.
  • Business Quant data shows Research & Development for HCWB at $1.4 million in Q3 2025, $1.2 million in Q2 2025, and $1.5 million in Q1 2025.